KCM
APLS

Kynam Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Kynam Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2M Sell
825,000
-83,607
-9% -$1.8M 2.05% 14
2025
Q4 		$22.8M Buy
908,607
+100,000
+12% +$2.35M 1.46% 19
2025
Q3 		$18.3M Buy
+808,607
New +$18.9M 1.36% 19
2023
Q1 		– Sell
-300,000
Closed -$15.5M – 36
2022
Q4 		$15.5M Buy
+300,000
New +$15.9M 2.38% 12

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Kynam Capital Management's APLS Position: Q1 2026 in Review

Kynam Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 9.2% in Q1 2026, selling an estimated $1.8M and leaving 825,000 shares worth $33.2M. The position accounts for 2.05% of the portfolio, ranked #14.

Kynam Capital Management first reported a position in APLS in Q4 2022 and has held it in 4 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Kynam Capital Management held 825,000 shares of Apellis Pharmaceuticals worth $33.2M as of Q1 2026.
  • Kynam Capital Management sold 83,607 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Apellis Pharmaceuticals made up 2.05% of Kynam Capital Management's portfolio in Q1 2026, its #14 holding.
  • Kynam Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.